Introduction
While older adults are disproportionately affected by cancer [1], few participate in clinical trials [2], limiting understanding of treatment tolerability and impact on aging. Technology can facilitate vulnerable older adult trial enrollment and inclusion of aging outcomes by collecting measures in the participants’ homes. Wearable sensors can quantify frailty, gait speed, endurance, and strength [3]. Symptoms can be monitored frequently over tablets or smartphones [4].
Digital health technology (DHT) includes platforms, software, and sensors to enhance disease management and healthcare delivery [5]. Older adults encounter challenges in DHT adoption, such as physical limitations, lack of perceived usefulness, and device complexity [6]. Additionally, DHT researchers grapple with the trade-offs between consumer-grade and research-grade devices. Consumer-grade devices limit data access and rely on black-box processing algorithms [7] while research-grade devices have closed ecosystems and higher costs [7]. Open-source technology that provides publicly available source code can foster collaboration and accessibility. By promoting innovation and tailoring solutions to specific research needs, we can create more effective and cost-efficient tools for both patients and healthcare professionals.
GeRI, an open-source technology platform, will be developed through a participatory design process for monitoring cancer treatment toxicity and aging metrics in older adults with cancer. The participatory design approach involves all stakeholders, including end-users, to ensure that the developed solution meets the needs and preferences of the intended users [8]. This pilot study will assess GeRI’s usability and satisfaction while actively collecting feedback from older patients with cancer and caregivers to drive platform improvements. This collaborative endeavor hopes to promote innovative tolerability studies, bridge the digital divide among older adults, and provide accessible solutions for providers and researchers.